Andrew Eckel

Andrew Eckel

Auto-generated profile, based on publicly available information

Andrew Eckel

Institute for Technology Assessment, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in JCO Oncology Practice
Verified
Journal Article
Closed access
MPMary Linton B Peters
Mary Linton B Peters
AEAndrew Eckel
Andrew Eckel
CSClaudia L. Seguin
Claudia L. Seguin
BDBarak Davidi
Barak Davidi
DHDavid H. Howard
David H. Howard
PPPari V. Pandharipande
Pari V. Pandharipande
PURPOSE: We evaluated the potential cost-effectiveness of combined magnetic resonance imaging (MRI) and endoscopic ultrasound (EUS) screening for pancreatic ductal adenocarcinoma (PDAC) among populations at high risk for the disease. METHODS: We used a microsimulation model of the natural history of PDAC to estimate the lifetime health benefits, costs, and cost-effectiveness of PDAC screening among populations with specific genetic risk factors for PDAC, including BRCA1 and BRCA2, PALB2, ATM, Lynch syndrome, TP53, CDKN2A, and STK11. For each high-risk population, we simulated 29 screening strategies, defined by starting age and frequency. Screening included MRI with follow-up EUS in a subset of patients. Costs of tests were based on Medicare reimbursement for MRI, EUS, fine-needle aspiration biopsy, and pancreatectomy. Cancer-related cost by stage of disease and phase of treatment was based on the literature. For each high-risk population, we performed an incremental cost-effectiveness analysis, assuming a willingness-to-pay (WTP) threshold of $100,000 US dollars (USD) per quality-adjusted life year (QALY) gained. RESULTS: For men with relative risk (RR) 12.33 ( CDKN2A) and RR 28 ( STK11), annual screening was cost-effective, starting at age 55 and 40 years, respectively. For women, screening was only cost-effective for those with RR 28 ( STK11), with annual screening starting at age 45 years. CONCLUSION: Combined MRI/EUS screening may be a cost-effective approach for the highest-risk populations (among mutations considered, those with RR >12). However, for those with moderate risk (RR, 5-12), screening would only be cost-effective at higher WTP thresholds (eg, $200K USD/QALY) or with once-only screening.

1 September 2021 in Radiology
Verified
Journal Article
Closed access
MHMark M. Hammer
Mark M. Hammer
AEAndrew L. Eckel
Andrew L. Eckel
LPLauren L. Palazzo
Lauren L. Palazzo
CKChung Yin Kong
Chung Yin Kong
In CT lung cancer screening, the optimal cost-effective strategy for subsolid nodules does not treat ground-glass nodules and has a threshold solid component size of 4 mm. Background Guidelines such as the Lung CT Screening Reporting and Data System (Lung-RADS) are available for determining when subsolid nodules should be treated within lung cancer screening programs...

31 May 2022 in Pancreatology
Verified
Journal Article
Closed access
MPMary Linton B Peters
Mary Linton B Peters
AEAndrew Eckel
Andrew Eckel
ALAnna Lietz
Anna Lietz
CSClaudia Seguin
Claudia Seguin
PMPeter Mueller
Peter Mueller
PPPari V. Pandharipande
Pari V. Pandharipande

7 May 2026 in Journal of Medical Screening
Verified
Journal Article
Closed access
CSClaudia L Seguin
Claudia L Seguin
ALAndrea Luviano
Andrea Luviano
KKKaren M Kuntz
Karen M Kuntz
MLMartin Lajous
Martin Lajous
MMMonica Isabel Meneses-Medina
Monica Isabel Meneses-Medina
AKAmy B Knudsen
Amy B Knudsen
Objectives: Given steady increases in age-standardized colorectal cancer incidence, health authorities in Mexico could consider implementing a colorectal cancer screening program. To inform program design, we evaluated the cost-effectiveness of fecal immunochemical testing (FIT) among a hypothetical cohort of 45-year-old residents of Mexico City. We adapted a validated US microsimulation model of colorectal cancer to reflect epidemiological outcomes in Mexico City. Methods: Using the adapted model, we estimated the lifetime health outcomes and costs associated with no screening and with FIT strategies that varied by the start age, end age, screening interval, and hemoglobin threshold for colonoscopy referral. We obtained costs from published reports and formularies. We calculated incremental cost-effectiveness ratios and identified the cost-effective FIT strategy as the strategy with the highest ratio below the willingness-to-pay threshold of 381,000 MXN per quality-adjusted life-year (QALY) gained (i.e., three times Mexico's per-capita Gross Domestic Product). Results: Compared with no screening, the effectiveness of FIT screening ranged from 23 to 49 QALYs gained per 1000 45-year-olds. Biennial FIT from age 50 to 70 with the most lenient threshold for colonoscopy referral (10 μg of hemoglobin/g of feces) was the cost-effective strategy. The starting age of screening was sensitive to assumptions about the cost of unreturned test kits, outreach costs, and colorectal cancer risk. Conclusions: Screening for colorectal cancer with FIT may be cost-effective in Mexico City. Additional studies are needed to assess whether the colonoscopy capacity is sufficient to support a lenient referral threshold.